Insider · CIK 0001792150
Merdad Parsey
Files at GILD (GILEAD SCIENCES, INC.), ARDX (ARDELYX, INC.), AVBP (ArriVent BioPharma, Inc.). First filing Nov 7, 2024, latest Nov 29, 2024.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
GILD: GILEAD SCIENCES, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 40Moderate | GILEAD SCIENCES, INC. | $15M 164,211 shares | -67% | - | |
| 18Weak | GILEAD SCIENCES, INC. | $2.3M 25,590 shares | -20% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 18, 2025 | ARDX ARDELYX, INC. | AGrant or award Common Stock | +15,235 | $0.00 | $0 | 57,291 | Jun 23, 2025 |
| Jun 18, 2025 | AVBP ArriVent BioPharma, Inc. | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +15,502 | $0.00 | $0 | 15,502 | Jun 20, 2025 |
| Apr 28, 2025 | ARDX ARDELYX, INC. | AGrant or award Common Stock | +42,056 | $0.00 | $0 | 42,056 | May 14, 2025 |
| Apr 28, 2025 | ARDX ARDELYX, INC. | AGrant or award Stock Option (Right to Buy)derivative | +64,457 | $0.00 | $0 | 64,457 | May 14, 2025 |
| Apr 28, 2025 | AVBP ArriVent BioPharma, Inc. | AGrant or award Stock Option (right to buy)derivative | +28,346 | $0.00 | $0 | 28,346 | Apr 29, 2025 |
| Dec 10, 2024 | GILD GILEAD SCIENCES, INC. | MOption exercise Common Stock | +3,820 | - | - | 84,621 | Dec 11, 2024 |
| Dec 10, 2024 | GILD GILEAD SCIENCES, INC. | FTax withholding Common Stock | -1,771 | $92.34 | $164k | 82,850 | Dec 11, 2024 |
| Dec 10, 2024 | GILD GILEAD SCIENCES, INC. | MOption exercise Restricted Stock Unitderivative | -3,820 | - | - | 36,753 | Dec 11, 2024 |
| Nov 27, 2024 | GILD GILEAD SCIENCES, INC. | MOption exercise Common Stock10b5-1 | +57,294 | $57.92 | $3.3M | 156,893 | Nov 29, 2024 |
| Nov 27, 2024 | GILD GILEAD SCIENCES, INC. | MOption exercise Common Stock10b5-1 | +88,119 | $65.38 | $5.8M | 245,012 | Nov 29, 2024 |
| Nov 27, 2024 | GILD GILEAD SCIENCES, INC. | SOpen-market sale Common Stock10b5-1 | -57,294 | $91.79 | $5.3M | 187,718 | Nov 29, 2024 |
| Nov 27, 2024 | GILD GILEAD SCIENCES, INC. | SOpen-market sale Common Stock10b5-1 | -88,119 | $92.00 | $8.1M | 99,599 | Nov 29, 2024 |
| Nov 27, 2024 | GILD GILEAD SCIENCES, INC. | SOpen-market sale Common Stock10b5-1 | -5,200 | $91.80 | $477k | 94,399 | Nov 29, 2024 |
| Nov 27, 2024 | GILD GILEAD SCIENCES, INC. | SOpen-market sale Common Stock10b5-1 | -3,199 | $91.80 | $294k | 91,200 | Nov 29, 2024 |
| Nov 27, 2024 | GILD GILEAD SCIENCES, INC. | SOpen-market sale Common Stock10b5-1 | -10,399 | $92.00 | $957k | 80,801 | Nov 29, 2024 |
| Nov 27, 2024 | GILD GILEAD SCIENCES, INC. | MOption exercise Non-qualified Stock Option (Right to Buy)derivative10b5-1 | -57,294 | $0.00 | $0 | 64,376 | Nov 29, 2024 |
| Nov 27, 2024 | GILD GILEAD SCIENCES, INC. | MOption exercise Non-qualified Stock Option (Right to Buy)derivative10b5-1 | -88,119 | $0.00 | $0 | 196 | Nov 29, 2024 |
| Nov 6, 2024 | GILD GILEAD SCIENCES, INC. | MOption exercise Common Stock10b5-1 | +25,000 | $57.92 | $1.4M | 125,189 | Nov 7, 2024 |
| Nov 6, 2024 | GILD GILEAD SCIENCES, INC. | SOpen-market sale Common Stock10b5-1 | -20,590 | $91.50 | $1.9M | 104,599 | Nov 7, 2024 |
| Nov 6, 2024 | GILD GILEAD SCIENCES, INC. | SOpen-market sale Common Stock10b5-1 | -5,000 | $91.50 | $458k | 99,599 | Nov 7, 2024 |
| Nov 6, 2024 | GILD GILEAD SCIENCES, INC. | MOption exercise Non-qualified Stock Option (Right to Buy)derivative10b5-1 | -25,000 | $0.00 | $0 | 121,670 | Nov 7, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.